Stocks New York: vaccination suspension slows Dow - Nasdaq in record mood

NEW YORK (dpa-AFX) - The possible preliminary out of vaccinations with the active ingredient from Johnson & Johnson (J&J) in the USA has the Dow Jones Industrial somewhat burdened on Tuesday. The US leading index fell 0,41 percent to 33 points. Johnson & Johnson shares were among the biggest losers in the Dow, down two percent. The technology-heavy one stock market Nasdaq, on the other hand, rose to new records.

Following reports of sinus vein thrombosis that occurred after vaccination with the active ingredient from Johnson & Johnson in the USA, the responsible US authorities recommended a temporary suspension of vaccinations. This will probably only be maintained for a few days. The US pharmaceutical company is also postponing the launch of the vaccine in Europe.

In contrast to the Dow, the Nasdaq 100 rose by 0,97 percent to 13 points and reached another record high. The next round mark of 953 points is getting closer and closer. The index was driven by the two heavyweights Tesla and Apple. For the market-wide S&P 14 it went up by 0,16 percent to 4135 points - also to a record high.

While Johnson & Johnson's share price fell, the stocks of its competitors in the global corona vaccine business, Biontech and Moderna, rose 5,1 percent and 6,6 percent, respectively.

The Dow Jones Industrial was also burdened by the price losses of Goldman Sachs and JPMorgan of more than one percent each. Both investment banks will publish their reports on the first quarter of the business on Wednesday before the starting bell.

At American Airlines, the news that the airline expects an adjusted loss of 2,8 billion US dollars for the first quarter caused a price loss of three percent.